Investigating how three antiviral drugs work together to treat COVID-19
Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir
This study is looking at how three antiviral drugs for COVID-19 work together and how to get them to the right parts of the body, with the goal of finding better ways to help patients recover, especially from lung symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11036342 on NIH RePORTER |
What this research studies
This research focuses on understanding how the antiviral drugs molnupiravir, nirmatrelvir, and remdesivir interact with each other and how they can be effectively delivered to target organs in the body. The study examines the metabolic processes of these drugs, including how they inhibit the replication of the SARS-CoV-2 virus, which causes COVID-19. By exploring the combination and delivery strategies of these medications, the research aims to enhance their effectiveness in treating COVID-19 symptoms, particularly those affecting the lungs. Patients may benefit from insights into optimized treatment protocols that could improve recovery outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with COVID-19 who may benefit from antiviral treatment.
Not a fit: Patients who are not infected with COVID-19 or those who have contraindications to the studied antiviral medications may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for COVID-19, potentially improving recovery rates and reducing severity of symptoms.
How similar studies have performed: Previous research has shown promising results with antiviral treatments for COVID-19, indicating that this approach has potential for success.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Yan, Bingfang — University of Cincinnati
- Study coordinator: Yan, Bingfang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.